[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hematologic-malignacies\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hematologic-malignacies":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,46],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":4},"100646130","early-phase-1-efficacy-and-safety-of-megalt-injection-for-platelet-recovery-after-umbilical-cord-blood-transplantation-100646130",false,"NCT07696767","Efficacy and Safety of MegaLT Injection for Platelet Recovery After Umbilical Cord Blood Transplantation","Study of the Efficacy and Safety of MegaLT Injection for Promoting Platelet Recovery After Umbilical Cord Blood Transplantation","Inclusion Criteria:\n\n* Age ≥18 years, male or female.\n* Patients with a definite diagnosis of hematologic malignancy who are undergoing umbilical cord blood transplantation.\n* Patients at day 14 after umbilical cord blood transplantation.\n* ECOG performance status ≤2.\n* Patients who voluntarily agree to participate in this clinical trial, fully understand the study content, and sign the informed consent form.\n\nExclusion Criteria:\n\n* Patients with relapse of any malignant tumor.\n* Pregnant or lactating women.\n* Patients with severe infection or severe cardiac, hepatic, pulmonary, renal, neurologic, or metabolic disease.\n* Patients with a history of severe thrombotic events or known risk factors for thrombosis. Exception: participants for whom the investigator determines that the potential benefit of study participation outweighs the potential risk of thromboembolic events.\n* Patients with uncontrolled infectious disease or other serious diseases, including but not limited to infection such as HIV positivity, congestive heart failure, unstable angina, cardiac arrhythmia, psychosis, social circumstances that would limit compliance with study requirements, or any condition that the treating physician considers may pose unpredictable risks.\n* Patients with active hepatitis B or hepatitis C.\n* Patients who have previously received organ transplantation or are planning to receive organ transplantation, except for hematopoietic stem cell transplantation.\n* Patients who participated in another clinical study and used any investigational drug or device within 30 days before the baseline visit. Participation in observational studies is allowed.\n* Patients considered by the investigator to be unsuitable for participation in this clinical trial for any other reason.","ALL","18 Years",{"count":19,"type":20},7,"ESTIMATED","INTERVENTIONAL",[23],"EARLY_PHASE1","This is a single-arm, early safety and feasibility exploratory study to evaluate the efficacy and safety of MegaLT Injection in promoting platelet recovery after umbilical cord blood transplantation. Adults with malignant hematologic diseases who undergo umbilical cord blood transplantation will receive a single intravenous infusion of MegaLT Injection on day 14 after transplantation. Two dose levels will be evaluated sequentially, and platelet recovery, platelet transfusion requirements, and safety outcomes will be assessed.",[26,27,28],"Thrombocytopenia","Hematologic Malignacies","Platelet Recovery After Umbilical Cord Blood Transplantation",[30,31,32,33,26],"MegaLT Injection","Umbilical Cord Blood Transplantation","Platelet Recovery","Platelet Engraftment","NOT_YET_RECRUITING","2026-07-09",{"date":37,"type":38},"2026-07-10","ACTUAL",{"date":40,"type":20},"2026-07-31",{"date":42,"type":20},"2027-06-30",{"name":44,"class":45},"Anhui Provincial Hospital","OTHER_GOV",{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":21,"phases":56,"briefSummary":58,"conditions":59,"keywords":66,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":85},"100613720","reduced-dose-apixaban-and-rivaroxaban-versus-low-molecular-weight-heparin-in-patients-with-hematologic-malignancies-100613720","NCT07270263","Reduced-Dose Apixaban and Rivaroxaban Versus Low-Molecular-Weight Heparin in Patients With Hematologic Malignancies","Efficacy and Safety of Reduced-Dose Apixaban and Rivaroxaban Versus Low-Molecular-Weight Heparin in Patients With Hematologic Malignancies: A Prospective Randomized Study","HEM-DOAC","Inclusion Criteria:\n\n* Active hematologic malignancy at the time of initiation of systemic therapy, including multiple myeloma, myeloproliferative neoplasm, lymphoma or other hematologic cancer with a Khorana score ≥ 2 points (intermediate or high risk of venous thromboembolism, VTE)\n* Use of anticoagulant agents for primary thromboprophylaxis, including direct oral anticoagulants (DOACs) at reduced doses (apixaban 2.5 mg twice daily or rivaroxaban 10 mg once daily) or low-molecular-weight heparin (LMWH) (enoxaparin 40 mg subcutaneously once daily).\n\nExclusion Criteria:\n\n* Major bleeding within the last month (including gastrointestinal or intracranial bleeding).\n* Active major bleeding.\n* Hemoglobin concentration \\\u003C 8 g\u002FdL.\n* Thrombocytopenia with platelet count \\\u003C30 × 10⁹\u002FL.\n* ECOG performance status of 3 or 4.\n* Expected survival \\\u003C6 months.\n* History of mechanical heart valve or severe mitral stenosis.\n* Estimated glomerular filtration rate (eGFR) \\\u003C 25 mL\u002Fmin.\n* Hepatic impairment (ALT ≥ 3× upper limit of normal or bilirubin ≥ 2× upper limit of normal).\n* Acute coronary syndrome or ischemic stroke within the last 6 months.\n* Anticipated significant drug-drug interactions between DOACs and anticancer agents.\n* Known antiphospholipid syndrome (APS).",{"count":55,"type":20},100,[57],"NA","This study investigates the efficacy and safety of direct oral anticoagulants (DOACs) in comparison with standard low-molecular-weight heparin (LMWH) for the prevention of venous thromboembolism in patients with hematological malignancies. Eligible participants will be randomized to receive reduced-dose apixaban, reduced-dose rivaroxaban, or standard-dose LMWH. The primary objective is to evaluate the incidence of venous thromboembolism during a 6-month follow-up period. Secondary objectives include assessment of bleeding complications, overall survival, and treatment adherence. The results of this study may provide evidence for safer and more convenient thromboprophylaxis strategies in patients with blood cancers.",[60,61,62,63,64,65,27],"Lymphoma","Leukemia","Multiple Myeloma (MM), Lymphoma, Large B-Cell, Diffuse (DLBCL), Lymphoma","Venous Thromboembolic Disease","VTE (Venous Thromboembolism)","PE - Pulmonary Embolism",[67,68,69,70,71,72,73],"Apixaban","Rivaroxaban","Low-Molecular-Weight Heparin","Venous Thromboembolism","Cancer-Associated Thrombosis","Hematologic Malignancies","Direct Oral Anticoagulants","RECRUITING","2025-12-18",{"date":77,"type":38},"2025-12-26",{"date":79,"type":38},"2024-11-22",{"date":81,"type":20},"2026-12-31",{"name":83,"class":84},"Medical University of Gdansk","OTHER",1]